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The involvement of dysregulated c-myc expression has been well established in
certain virus- or chemical-induced and naturally developing tumors (1-5). Most of
murine plasmacytomas andhuman Burkitt'slymphomas have been showntocarry
achromosomaltranslocation involvingc-mycandIggenes (2-5). In suchtumorcells,
only the c-myc transcripts from the translocated allele are constitutively expressed,
while the normal allele is completely suppressed, suggesting that the translocation
affects the expression of the c-myc gene of the normal allele as well as that of the
translocated one (6, 7). Recently it has been shown that Ig heavy chain enhancer
(Ew)t-driven c-myc can induce immature B cell tumors in the transgenic mice (8),
which is a direct demonstration ofthe involvement ofthe translocated c-myc gene
in B lymphomagenesis. Moreover, tumors developed in such transgenic mice have
been demonstrated to be monoclonal or oligoclonal, suggesting that the malignant
transformation requires secondary events followinganabnormal expression ofc-myc
gene. It is likely that such events might be determined or influenced by factors in-
trinsicto certaincells, orbyenvironmentaland genetic factors. Thus, thetransgenic
mice carrying activatedoncogenes such as c-myccan alsobe auseful system to study
such factors influencing tumorigenesis.
To study the genetic or environmental factors that affect the myc-induced lym-
phomagenesis, we introduced the translocated human c-myc gene into two inbred
strains ofmice, C57BL/6 and C3H/HeJ, which have different geneticbackgrounds.
Wehave observedthe preferential development ofT lymphomas in C3H/HeJ trans-
genic mice, whereas B6 transgenic mice mostly developed B lymphomas. Further-
more, the bone marrow transfer experiments using prelymphomatous transgenic
mice suggest that environmental factors might influence the development ofT lym-
phoma in C3H/HeJ mouse.
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Materials and Methods
ProductionofTansgenicMice.
￿
The Ep-myc used is an 11.5-kb Eco RI fragment from a cosmid
DNA clone, cU23, derived from the non-Hodgkin's lymphoma Manca, which consists of
a translocated human c-myc gene fused head to head with the Cu gene (Fig. 1) (9). Transgenic
mice were produced by microinjecting -200 copies of the gene into the fertilized eggs of
C57BL/6 or C3H/HeJ mice as described (10). The offsprings were screened for the integra-
tion of the transgene by Southern blot analysis of DNA from tail tips using the Eco RI/Cla
I fragment of human c-myc gene as a probe.
Flow Cytometry Analysis.
￿
Flow cytometry analysis was performed using aFACS 440 equipped
with dual lasers. The mAbs used were FITC-conjugated anti-IgM (rat IgG), FITC-anti-
B220 (6112, rat IgG), FITC-anti-Lyt-2 (53-6, rat IgG), FITC-antiThy-1 .2 (30H12, rat IgG),
FITC-anti-I-Ab (25-9-17, mouse IgG2), biotinylated (bi)-anti-IgD (anti-5a or 5b), bi-anti-
B220, bi-anti-L3T4 (GK1.5, rat IgG), bi-anti-Ly-1 (53-7, rat IgG), bi-anti-I-Ek (13/4, mouse
IgG2a), and phycocyanin (PC)-labeled anti-CD3 (2011, hamster IgG). Single cell suspen-
sions were obtained from bone marrow, lymph node, spleen, and thymus in deficient RPMI
medium containing 3% FCS and 0.1% NaN3. Washed cells were incubated with several com-
binations ofvarious antibodies for 20 min at 4°C. After washing, Texas red avidin was added
as a second step to develop biotinylated antibodies. Propidium iodide was included for the
last 5 min ofa second step to staindead cells. The stained cellswere examined by multiparameter
FACS and the list mode data were collected into a VAX11/730 computer and analyzed by
a DESK program developed at Stanford University, Stanford, CA.
Southern BlotAnalysis.
￿
High molecular weight DNA was prepared with 250 Wg ofproteinase
K (Sigma Chemical Co., St. Louis, MO) in 2 ml of 1 x SSCA mM EDTA/0.Io7o NaDodS04
at 37°C for 3-12 h. After digestion, phenol, phenol/chloroform (1 :1, wt/vol), and chloroform
extractions were performed and DNA was precipitated with ethanol. 5 Rg of the DNA was
digested with Xba I for analysis of the Ig heavy chain locus and with Hind III for analysis
of the K chain locus and TCR a chainlocus. Digested DNA was separated on 0.5°70 agarose
gel, and transferred to Gene Screen Plus'"' Hybridization Transfer Membrane (NEN Re-
search Products, Boston, MA) in a solution of 0.4 N NaOH/0.6 M NaCl. Blots were hybrid-
ized with 32P-labeled DNA probes at 65'C in a buffer of 1 M NaCI/0.05 M Tris-HCl, pH
7 .5/200 Rg/ml salmon sperm DNA. Blots were washed in 2 x SSC at room temperature for
10 min, in 2 x SSC/logo SDS at 65'C for 60 min, in 0.1 x SSC at room temperature for 60
min, and processed by autoradiography. The DNA probes used in this study were a 3.8-kb
Xba I fragment of the mouse germline Jx region (11), a 1.7-kb Pst I/Eco RI fragment ofJK
(12), a 1.7-kb Pst I fragment of DO, region (13), and a 2.4-kb Hind III/Eco RI fragment
of D/32 region (13).
S1 Nuclease Protection Assay.
￿
Total RNA was prepared from lymphoma cells and prelym-
phomatous splenic cells and thymocytes by the guanidium isothiocyanate/CsC12 method (14).
SSDNA probe for S1 analysis was prepared as follows: an Xba I/Pst I fragment ofcU23 (9)
or an Sst I/Pvu II fragment of PKO-myc (6, 15, 16) was cloned into M13mp18 vector and
single-stranded 32P-labeled DNA was synthesized by the primer extension method (17). After
digestion with Xba I or Sst I, the ssDNA probe was separated by PAGE. For Sl protection
assay, 25 Rg of total RNA was co-precipitated with the specific DNA probes (100,000 cpm),
heated at 95'C for 10 min, and incubated for 14 h at 601C in 80% formamide/40 mM Pipes/0.4
M NaCl/ 1 mM EDTA. Hybridized materials were treated with 250 U of Sl nuclease (17)
for 40 min at 30'C in 280 mM NaCl/50 mM NaoAc (pH 4.6)/4.5 mM ZASo4/20 p.g/ml
salmon sperm DNA. After PAGE under denaturing conditions, Sl-resistant species were visual-
ized by autoradiography.
Bone Marrow or FetalLiver Transplantation.
￿
101 bone marrow cells treated with antiThy-1.2
(IgM mAb, DAIICHI Kagaku) plus complement (LOWTOX-M Rabbit Complement, Cedar
Lane Laboratories, Hornby, Ontario) and 5 x 106 of fetal liver cells from prelymphoma-
tous Ep.-myc mice were transferred into lethally irradiated normal B6 (878 rad) or normal
C3H/HeJ mice (950 rad). At the same time, 106 cells from bone marrow or fetal liverof the
same Ett-myc mice were inoculated intravenously into unirradiated syngeneic mice. Trans-
genic mice, whose cells did not induce tumors in unirradiated recipients, were recognized
as prelymphomatous ones.YUKAWA ET AL.
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FIGURE 1.
￿
Structure ofEIt-myctransgene. Asthe
transgene, an 11.5-kb Eco RI fragment containing
tJ
￿
the Cp-c-myc joining region (arrow: recombina-
tion site) was prepared from a cosmid DNA
clone(cU23) ofthe Manca cell line that has the
chromosomal translocation(t(8:14)(g24;g32)) in-
volving the Clc-c-mycjoining region. Exons are
shown by solid boxes. EA(E) is a transcriptional
enhancer element ofthe human heavy chain locus
(9). Restriction sites: RI, EcoRI; X, Xbal; P, Pstl.
Results
Developments ofBand TLineage Tumors in B6 and C3H/HJEp-myc TransgenicMice.
￿
Eit-
myc transgenic mice were produced by microinjecting fertilized eggs of both B6 and
C3H/HeJ mice with 11.5-kb DNA fragments containing human EA.-myc gene de-
rived from a non-Hodgkin lymphoma cell line, Manca. In nine independent B6 trans-
genic mice, lymphoma developed by 6 wk of age. The lymphomas involved mainly
the thymus, the spleen, and the lymph nodes in these mice. These lymphomas were
transplantable into normal syngeneic mice and could be adapted into in vitro cul-
ture. The analysis of surface phenotypes and rearrangements of Ig and TCR genes
demonstrated that eight of nine B6 transgenic mice developed lymphomas charac-
teristic of B cells. The B lymphomas that developed in the transgenic mice repre-
sented various stages of differentiation, as shown in Table I. For instance, a lym-
phoma in mouse 119 was at pre-B cell stage since the rearrangement ofheavy chain
gene but not oflight chain gene was observed. On the other hand, mouse 316 devel-
oped a tumor expressing a phenotype of mature B cells (IgM'/IgD'/B220'). As
shown in Fig. 2, one or few discrete rearrangements in JH and JK regions were ob-
served in all analyzed B lymphomas except for that certain pre-B cell lymphoma
that retained the germline configuration in the JK region. These rearrangement pat-
terns of Ig genes indicate that tumors developed in these mice are monoclonal or
TABLE I
Tumors Developed in C57BL/6 E#-myc Transgenic Mice
` Postnatal days when lymphadenopathy or splenomegaly was initially observed.
t Surface phenotypes were determined by two-color FAGS analysis.
S Rearrangements of Ig heavy chain UH), light chain (1K), and TCR S chain genes. G, germ-
line configuration; RI-R3 denote distinct rearranged patterns in each tumor.
fl Cell types of tumors were mainly determined on the basis of FAGS data.
Tissues from where the tumors were derived . S, spleen; T, thymus; M, mesenteric lymph-
node; I, inguinal lymphnode.
EW-myc
mice d`
Surface markers ofs
primary tumors JHS JKS TCR-OS Cell typell
93(S)l 40 IgM', IgD-, B220' Rt,G R1,G G B
119(S) 35 IgM-, IgD-, B220' RI,R2,R3,G G RI Pre-B
139(S) 42 IgM-, IgD- , B220' RI ,G G G Pre-B
229(M) 37 IgM', B220' Rt,R2 RI RI B
316(S) 42 IgM', IgD', B220' ND ND ND B
334(S) 40 IgM-, B220' ND ND ND Pre-B?
339(1) 36 IgM', B220' RI,G RI,R2 G B
346(S) 39 IgM', IgD- , B220' ND ND ND B
225(M) 35 CD4', CD8', Thy1 .2' ND ND ND T71 4
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FIGURE 2 .
￿
Monoclonal oroligoclonal tumors arose in B6 andC3H/HeJ EW-myc transgenic mice .
Southern blot analysis was performed with DNA from B6 liver, tumors of B6 transgenic mice
(93, 119, 139, 229, 339), C3H/HeJ liver, andtumors of C3H/HeJ transgenic mice (169, 273, 241,
480, 454). The blots were hybridized withJH, JK, DOI, D02 probes (see Materials andMethods) .
Rearrangements at the Ig heavy chain, light chain, andTCR 0 chain loci of tumors in B6 trans-
genic mice (a)andC3H/HeJ transgenic mice (b) are shown . Tissues from whereDNAwere pre-
pared . L, liver ; S, spleen; T, thymus ; M, mesenteric lymphnode ; I, inguinal lymphnode ; A, axil-
lary lymphnode .
oligoclonal . One pre-B cell lymphoma developed in mouse 119 and a B cell lym-
phoma in mouse 229 had also the rearrangement ofTCR /3 chain gene . One mouse
(225), developed aCD4+ , CD8+ , Thy-1.2' lymphoma . These results indicate that
Ej,-myc B6 transgenic mice mostly develop B cell tumors although these mice also
have a potential to develop T cell tumors at low frequencies .
Seven C3H/HeJ transgenic mice carrying EI,-myc gene were produced . Around
5 wk of age, all developed lymphomas that involved mainly the mesenteric lymph
nodes and the spleen but rarely the thymus . In contrast to B6 transgenic mice, six
ofseven C3H/HeJ transgenic mice developed lymphomas that expressTcell pheno-
types . B cell lymphoma arose only in one C3H/HeJ transgenic mouse (454) . The
surface phenotypes of the tumors developed in these mice are summarized in Table
II and representative FAGS analyses are shown in Fig . 3 . The differentiation stages
ofTlymphomas were variable in each C3H/HeJtransgenic mice . Forinstance, lym-
phomas that developed in mouse 480 expressed both CD4 andCD8. Mice 241 and
450 developed CD4+/CD8 - and CD4-/CD8+ tumors, respectively. Some lym-YUKAWA ET AL.
TABLE II
Turnors Developed in C3H/Hej E#-myc Transgeneic Mice
' Postnatal days when lymphadenopathy or splenomegaly was initally observed.
t Surface phenotypes were determined by two-color FAGS analysis.
§ Rearrangements of Ig heavy chain (JH), light chain (ht) and TCR-/3 genes. G, germline
configuration; RI and R2 denote the distinct rearrangement patterns in each tumor.
II Cell types of tumors were mainly determined on the basis of FACS analysis .
Tissues from where tumor cells were prepared. M, mesenteric lymphnode; I, inguinal lymph-
node; A, axillary lymphnode; S, spleen; T, thymus.
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phomas were found to consist of two or three subpopulations expressing distinct
phenotypes: CD4'/CD8+ and CD4-/CD8+ in mouse 169 and CD4'/CD8-,
CD4-/CD8+ and CD4-/CD8- in mouse 273. As shown in Fig. 2, in Southern blot
analysis of T cell tumors developed in C3H/HeJ transgenic mice, the discrete bands
representing the rearranged TCR /3 chain gene were observed in each tumor, indi-
cating that these T cell tumors are monoclonal or oligoclonal. Two tumors derived
from mesenteric lymph nodes and inguinal lymph nodes ofmouse 169 showed dis-
tinct patterns ofTCR0 gene rearrangement although they displayedsimilar surface
phenotypes (CD4'/CD8+ and CD4-/CD8+), demonstrating that two tumors could
arise independently in a single transgenic mouse. However, tumor cells expressing
distinct phenotypes in each lymph node of this mouseappear to be ofthe same clonal
origin. For example, tumor cells from a mesenteric lymph node showed only two
rearranged bands and no germline band of TCR(3 gene. This result suggests that
cells might be differentiating from CD4'/CD8' to CD4-/CD8' in these tumors.
Although three subpopulations of tumor cells were found in mouse 273, we could
not determine from their rearranged pattern of TCR /3 chain gene whether each
subpopulation was derived from a single clonal origin. The rearrangement of JH
gene was also observed in these tumors, except in lymphomas developed in mesen-
teric lymph nodes of mouse 169 and in spleen of mouse 241, which conserved the
germline configuration ofJH alleles. These results indicate that, in contrast to B6
transgenic mice, C3H/HeJ transgenic mice preferentially develop T cell tumors.
LymphocyteActivation and EEc-myc mRNA Expression in Eft-myc Transgenic mice at the Pre-
lymphomatous Stage.
￿
The above results suggest the possibility that the strain depen-
Ep-myc
mice d'
Surface markers oft
primary tumors i's JK4 TCR-O§ Cell typell
169(M)' 30 CD4', CD8', CD3', Thy-1 .2' G G Ri,R2 T
CD4-, CD8', CD3', Thy-1 .2`
169(I) 30 CD4', CD8', CD3', Thy-1 .2' Rj,G G RI T
CD4-, CD8', CD3', Thy-1 .2'
272(M) 35 CD4', CD8', CD3', Thy-1 .2' ND ND ND T
273(A) 33 CD4', CD8- , CD3', Thy-1 .2' Ri,G ND Rt,R2,G T
CD4-, CD8', CD3', Thy-1 .2'
CD4-, CD8- , CD3', Thy-1 .2'
241(S) 35 CD4', CD8- , CD3', Thy-1 .2' G ND R,,G T
450(S) 30 CD4-, CD8', CD3', Thy-1 .2' RI,G G RI,G T
480(S) 34 CD4', CD8*, CD3', Thy-1 .2' RI,G ND R1,R2,G T
454(T) 35 IgM', 13220' RI R,,G Ri,G B716
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FIGURE 3 .
￿
Surface phenotypes of the tumors developed in C3H/HeJ Ep-myc transgenic mice .
Tumors developed in mouse 169 (a), mouse273 (b), mouse 241 (c), andmouse480 (d) were stained
with biotinylated anti-CD4, FITC anti-CD8,TRAV, and PI . Vertical axis representsCD4(TR)
and horizontal axis means CD8(FITC). (a)CD4'/CD8' andCD4-/CD8* T lymphomas devel-
oped in mesenteric lymphnode of mouse 169 . (b) CD4'/CD8-, CD4-/CD8', and CD4-/CD8-
T lymphomas in axillary lymphnode of mouse 273 . (c) CD4'/CD8-T lymphoma i
mouse 241 . (d) CD4'/CD8' T lymphoma in spleen of mouse 480 .
dency ofB andT lymphoma development might be due to preferential activation
of B- orT -lineage cells in B6 or C3H/HeJ transgenic mice, respectively. To test this
possibility, we analyzed the size and surface phenotypes ofbone marrow cells, spleen
cells, and thymocytes from the prelymphomatous transgenic mice that had not de-
veloped tumors. As shown in Fig . 4, B220+ cells from bone marrow and spleen of
both B6 and C3H/HeJ transgenic mice were found to be larger in size and strongly
expressed class II antigens compared with those ofnormal mice, indicating that B-
lineage cells were similarly activated in prelymphomatous transgenic mice of both
strains . However, cell size and numbers of each T cell subsets in thymus derived
from both B6 andC3H/HeJ transgenicmice were normal, as shown in Fig . 5 . These
results suggest that high frequency ofT lymphoma development inC3H/HeJ trans-
genic mice may not be simply due to the preferential activation ofT lymphocytes .
The second possible explanation for a high incidence ofT lymphoma in C3H/HeJ
mice is that the EA.-myc gene might be expressed in Tlineage cells ofC3H/HeJ mice
but not ofB6 mice . To determine whether there is any difference ofEj.-mycmRNA
expression among B andT lymphomas as well as prelymphomatous T and B cells
from B6 and C3H/HeJ transgenic mice, RNAs were prepared from these cells and
the expression of the transgene was analyzed . As shown in Fig . 6, four protected
bands were observed in B and T lymphomas derived from B6 and C3H/HeJ trans-
genic mice, respectively, when the fragment ofhumangenomic c-mycDNAwas usedYUKAWA ET AL .
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FIGURE 4 .
￿
Characterization ofbone marrow cellsand splenocytes from prelymphomatous Ep,-
myc B6 (a-c) and C3H/HeJ (dJ) mice . Solid lines denote Ew-myc cells, and broken lines denote
normal cells . (a) Class II antigen expression on B220+ bone marrow cells between B6 transgenic
(solid line) andnormal littermates (broken line) are compared by fluorescence intensities . (b) Sizes
ofB220+ bone marrow cells from B6 mice. (c) Sizes of B220+ splenocytes from B6 mice. (d) Class
II antigens expression on B220* bone marrow cells from C3H/HeJ mice. (e) Sizes ofB220+bone
marrow cells from C3H/HeJ mice. (f) Sizes of B220' splenocytes from C3H/HeJ mice . Three
independent prelymphomatous B6 or C3H/HeJ transgenic mice were examined . The represen-
tative FAGS profiles ofone B6 and oneC3H/HeJ transgenic mouse were presented in the figure,
since all analyzed mice showed simi
FIGURE 5 .
￿
Characterization ofthy-
mocytes from prelymphomatous
Ep-mycB6 andC3H/Hejmice. (a)
Sizesofthymocytes from B6 trans-
genic (solid line) and normal litter-
mates(broken line) are compared by
forward light scatter . (b) Staining
pattern forCD4 vs.CD8ofthymo-
cytes from normal B6 mice . (c)
Staining pattern for CD4 versus
CD8 ofthymocytesfrom Ep-myc B6
mice. (d) Sizes ofthymocytes from
C3H/HeJ transgenic (solid line) and
normal littermates (broken line) . (e)
Staining pattern for CD4 versus
CD8 of normal C3H/HeJ thymo-
cytes . (f) Staining pattern forCD4
versus CD8 of Ep.-myc C3H/
HeJ thymocytes . Three indepen
dent pre-lymphomatous B6 or C3H/HeJ transgenic mice were examined. The representative FAGS
profiles of one B6 and one C3H/HeJ transgenic mouse were presented in the figure since all analyzed
mice showed the similar patterns.HOMAGENESIS IN Eju-myc TRANSGENIC MICE
FiGuPE 6.
￿
S1 nuclease protection assay of transgenic and endogenous c-myc RNAtranscrip-
tion . (Left) Thehuman specific c-myc probewashybridized with total RNAs prepared from M12
(mouse B cell line), 169T (C3H/Hej EIA-myc Tlymphoma), 93B (B6E 'U-myc Blymphoma), B6
prelymphomatous EIA-myc spleen, 86 prelymphomatous EA-mycthymus, C3H/Hej prelymphoma-
tons EIA-myc spleen,C3H/Hej prelymphomatous EA-W thymus,B6 normal spleen, andB6 normal
thymus . Thereported cryptic promoters in intron I ofhuman c-myc were indicated (* and **)
and represented by protected bands of -774 and -760 nucleotides . Bands of -660 and -618
nucleotides also represent the probes specifically protectedbyhuman c-myc gene transcripts. (Right)
The mouse-specific c-myc probe wasused for 51 nuclease analysis. Mouseendogenous c-myctran-
scripts were detected at 188 nucleotides . In addition to mice shown in this figure, one B6 and
two C3H/Hej transgenic mice were examined and also found to express almost equal amounts
ofhuman c-myc mRNA in the spleen andthethymus . FAGS analysis showed that B220' B cells
in the thymus from aB6 transgenic, acontrol 86,aC3H/Hej transgenic, and a controlC3H/Hej
mouse were 1.7, 1.1, 1.3, and 1.0%, respectively, indicating that EA-myc mRNA in
of transgenic mice is not due to contaminating B cells.
as a probe. Thetwo larger bands of-774 and 460 nucleotides represent themRNA
transcribed from cryptic promoters in intron I of thehuman c-myc gene as previ-
ously reported (9) . Smaller but intense bands of-660 and -618 nucleotides were
consistently observed in lymphomas from transgenic mice but not in control cells,
indicating that these bands also represented the transcripts ofhuman c-myc gene.i
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These four bands were also observed in splenocytes and thymocytes from prelym-
phomatous B6 and C3H/HeJ transgenic mice but not in those of control mice. Ex-
pression levels ofEli-myc mRNA were found to be almost comparable among spleno-
cytes and thymocytes in both strains. Endogenous murine c-myc expression was
completely inhibited in B and T lymphomas ofboth strains. The expression ofmu-
rine c-myc mRNA was lower in prelymphomatous B and T cells of transgenic mice
than in those of normal mice. These results demonstrated that the Ep-rnyc gene is
equally expressed in prelymphomatous B and T cells from B6 and C3H/HeJ trans-
genic mice, and that the expression of endogenous c-myc gene was suppressed in
cells expressing Ep,-myc mRNA.
Transfer of Bone Marrow or Fetal Liver Cellsfrom Prelymphomatous Tansgenic Mice into
Normal Mice. No differences of Ep.-myc expression and lymphocyte activation were
observed between B6 and C3H/HeJ transgenic mice. These results suggested the
possibility that environmental factor(s) may enhance the development or the growth
of B and T lymphomas in B6 and C3H/HeJ transgenic mice, respectively. However,
it was impossible to carry out the crossing experiment ofthe transgenic mice to study
this possibility, since such mice died from tumors before giving rise to progeny. There-
fore, bone marrow or fetal liver transfer experiments were done by using primary
transgenicmice. Bone marrow or fetal liver cellsof prelymphomatous B6 or C3H/HeJ
transgenic mice were transferred into lethally irradiated normal B6 and C3H/HeJ
mice, and the recipient mice were monitored for the development of tumors for 1
yr. 10 of 11 B6 and 7 of 9 C3H/HeJ recipients developed lymphomas between 65
and 95 d after transplantation. As shown in Table III, 6 of 9 C3H/HeJ mice trans-
ferred with bone marrow cells from either B6 or C3H/HeJ transgenic mice devel-
oped T lymphomas within 3 mo. Only one C3H/HeJ, which received bone marrow
TABLE III
Bone Marrow or Fetal Liver Transfer from Ea-myc Transgenic Mice
to B6 and C3HIHef Mice
Bone marrow cells (5 x 106-1 x 107) or fetal liver cells (5 x 106) from Ep.-
myc transgenic mice were transplanted into irradiated normal B6 or C3H/HeJ
mice. Thecell type of tumors developed in recipients were determined by multi-
parameter FAGS analysis.
Donor cells were prepared from bone marrow or fetal liver of B6 transgenic
mice (91, 3-22, 3-24-2, 3-24-5, 3-25) and C3H/HeJ transgenic mice (4-30).
Bone marrow or fetal liver cells from a single donor were transfered into one
or several recipients; bone marrow of 91 to oneB6, fetal liver of 3-22 to one
B6, fetal liver of 3-24-2 to two B6 and two C3H/HeJ, fetal liver of 3-24-5 to
two B6 and twoC3H/HeJ, bone marrow of3-25 to two B6 andtwo C3H/HeJ,
and bone marrow of 4-30 to three B6 and three C3H/HeJ recipients.
Number of recipient mice.
Number of recipient mice that developed B (B) or T lymphomas (T) or no
lymphoma ( -).
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Tumors
B6
developed
recipients
in Tumors
C3H/HeJ
developed
recipients
in
Donors' nt BS TS ( -)S nT BS TS ( -)S
B6 transgenic 8 4 4 0 6 1 3 2
C3H transgenic 3 1 1 1 3 0 3 0
Total 11 5 5 1 9 1 6 2720
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cells from B6 transgenic mice, developedB lymphoma. This indicates that hemato-
poietic stem cells from B6 as well as C3H/HeJ transgenic mice can give rise prefer-
entially to T lymphomas in C3H/HeJ recipients . When bone marrow or fetal liver
cellsfrom B6 transgenic mice were transferred into irradiatedB6 recipients, the de-
velopment ofT lymphomas increased up to 50%. This result indicates that the fre-
quency ofTlymphoma development increases in the environment ofirradiated B6
mice, since primaryB6 transgenic mice mostly developed B lymphomasas described
earlier. To determinewhethertumors developed in recipients were derived from in-
dependent clonal origins, we analyzed the integration ofthetransgene and the rear-
rangements of Ig heavy chain andTCR 0 chain genes in B andT lymphomas de-
rived from different recipients that had been transferred with bone marrow cells
from the same B6 transgenic mouse (3-25) . Bone marrow cells from this mouse (3-
25) were transferred into two B6 and two C3H/HeJ recipients . B lymphomas devel-
oped in one B6 and one C3H/HeJ recipient and T lymphomas developed in the
others . As shown in Fig . 7, alllymphomasthat developed in different recipients showed
the Eu,-myc integrationand the distinct rearrangementpattern ofIg heavy chain and
TCR /3 chain genes, indicating that these tumors are derived from the same donor
bone marrow, but different clonal origins . Allthese results suggest thatTlymphomas
FIGURE 7 .
￿
Tumors of distinct clonal origins were developed in respective recipients that were
transferred with bone marrow cells from a single Ep-myc transgenic mouse . 10 7 bone marrow
cells from the B6 transgenic mouse (3-25) were transferred into twoB6 andtwoC3H/HeJ recip-
ient mice. DNA were prepared from tumors developed in each recipient mouse and analyzed
for the rearrangements of Ig heavy chain andTCR S chain genes . Integration of the EW-myc
transgene in these tumors demonstrated that they were of donor origin. 3-25-B6 (B): B lym-
phoma developed in one B6 recipient . 3-25-136 (T): T lymphoma developed in another B6 re-
cipient. 3-25-C3H (T): Tlymphoma developed in one C3H recipient . 3-25-C3H (B): Blym-
phoma developed in anotherC3H recipient . 3-25 tail : the DNAextracted from the tail of 3-25
Ep-myc B6 transgenic mouse . B6 liver : the DNA extracted from the liver of 136 mouse .YUKAWA ET AL.
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preferentially develop or grow in the environment of C3H/HeJ mice, and that ir-
radiated mice might provide the similarenvironmentthat supports the development
of T cell tumors.
Discussion
In this study, we have produced transgenic mice carrying theEp-mycgene by microin-
jecting the transgene into B6 or C3H/HeJ fertilized eggs and have shown that both
B and T cell lymphomas can arise in these mice. Most lymphomas that developed
in B6 transgenic mice were of B cell type as expected from the construction of the
transgene in that human c-myc gene was under the control of Ig enhancer element.
In contrast to B6 transgenic mice, C3H/HeJ transgenic mice preferentially devel-
oped T cell tumors. Several studies on productions of transgenic mice carrying Ep-
mychave been reported (8, 18, 19). Such transgenic mice have been shown to develop
mostly pre-Bcell tumors. Thesefindings are in striking contrast to ourresults. However,
they have injected the transgene into (B6 x SJL)F2 or (B6 x CDI)Fl, both of which
retain partiallyB6 background. Moreover, the SJLstrain has been shown to develop
frequently spontaneous reticulum cell sarcomas that are of pre-B cell origins (20).
Thus, our results raised the possibilities that the strain dependency of B or T lym-
phoma development might exist. Therefore, it is interesting to know what deter-
mines thedevelopment ofB or T lymphoma in ourB6 or C3H/HeJ transgenic mice,
respectively.
The phenotypic analysis of lymphocytes from B6 and C3H/HeJ transgenic mice
at a prelymphomatous stage showed increasesin cell size and MHC class II expres-
sion ofB cells from such mice of both strains, which is in good agreement with the
finding by Langdon et al. (21). However, the expression of Ep-myc transgene did
neither perturb the development of T cells in thymus or increase the size of T cells
in the transgenic mice of both strains. The S1 nuclease analysis of splenocytes and
thymocytes demonstrated that almost equal amounts of human c-myc mRNA were
expressed in spleens andthymuses ofboth strainsoftransgenic mice, indicating that
there is no difference in the transgeneexpression in B andTcells of B6 andC3H/HeJ
transgenic mice. These results suggest that a high incidence of B or T lymphomas
in B6 or C3H/HeJ transgenic mice couldnot be simply explained by the differential
activation of or the differential Ep-myc expression in B or T lineage cells.
In contrast to ourtransgenic mice, the Eli-myctransgenic mice produced by others
(8, 18, 21, 22) have been shown to express the transgene specifically in B lineage
cells. The reason for this discrepancy is not clear at the moment. However, it has
been reported that the transgenic mice introduced with productively rearranged p
chain gene express the transgene in certain population of T as well as B cells (23).
Furthermore, several pieces of evidence have also been reported that Ig enhancer
element can be active in T as well as B cells (24-27). Thus it is reasonable to assume
that the expression of human c-myc gene is also under the influence of the adjacent
Ig enhancer even in T cells. We used the human Ep-myc gene cloned from a non-
Hodgkin lymphoma, Manca, in which human Ig enhancer has been translocated
into intron 1 ofthe c-mycgene (9). Otherstudiesused the Ep-myc construct, in which
the mouse or the human c-myc gene is under the control of the murine Ig enhancer
(8, 18, 19). One of the three was the naturally translocated Ep-myc and the others
were theartificially constructed ones. Therefore, it is possible that the extent ofEu-myc722
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gene expression in T cells may reflect particular constructs. It should be noted that
the EA-myc construct used in this study lacks exon 1. The exon 1 is known to be
lost in the translocated c-myc gene of some of human Burkitt's lymphoma cells and
murine plasmacytoma cells (5). v-myc also lacks the equivalent sequence (28-30).
Some investigators have proposed that the exon 1 sequence plays an important role
in the negative control of c-myc gene transcription (31-33). Others have suggested
that the untranslated sequence ofc-mycmRNA derived from exon 1 may be involved
in the translational control (34, 35). Furthermore, it has been also reported that
c-mycmRNA lackingexon 1 sequence is more stable than the complete c-mycmRNA
(36-38). It is thus possible that our transgene might be more active than the myc
construct used by others, which contained exon 1 (8, 18) or heterologous SV40 pro-
moter (19). Alternatively, the EI.-myc transcripts of the transgenic mice produced
here might be more stable.
There are two possible explanations for a high incidence of T lymphoma in the
C3H/HeJ transgenic mice; (a) thefrequency oftransformation of B and T cells might
be intrinsically determined, or (b) the development or growth of T lymphoma in
C3H/HeJ mice might be accelerated by certain environmental factors such as growth
factors or endogenous viruses. One piece of evidence supporting the former possi-
bility is that the C3H/HeJ strain has a functional defect in B cells and is a low re-
sponder to LPS (39, 40). Therefore, this defect might be involved in less frequent
B lymphoma development in transgenic mice of this strain . However, we could not
observe any difference in EA.-myc-induced distortion of B lymphocyte activation in
prelymphomatous transgenic mice of both strains, as discussed above, suggesting
that the defect of C3H/HeJ did not affect Eu-myc-induced B cell activation.
The microenvironment of each strain is also an important factor that influences
the growth or development of lymphomas. When the bone marrow or fetal liver
cells from the prelymphomatous B6 or C3H/HeJ transgenic mice were transferred
to lethally irradiated C3H/HeJ mice, the developed lymphomas were mostly of T
cell type. Half of the tumors developed in irradiated B6 mice, which received
hemopoietic stem cells from B6 and C3H/HeJ transgenic mice, were also of T cell
type. Although the number of experiments was small because of the limited avail-
ability of transgenic mice, these resultsindicate the presence of the necessary condi-
tions in C3H/HeJ to support the growth or the development ofTlymphomas, respec-
tively. Furthermore, irradiation might modify the environment of B6 mice, resulting
in increased development of T cell lymphomas.
One of the environmental factors affectinglymphoma development in the trans-
genic mice might be an endogenous retrovirus. Recently, Klinken et al. (41) demon-
strated that v-rafcould convert the phenotype of B lymphomas developed in EI.-myc
transgenic mice to that of macrophages. This suggests that retrovirus infection could
have an influence on the lineage determination of tumors. However, the high inci-
dence of T lymphomas in C3H/HeJ transgenic mice cannot be explained simply
by the phenotype conversion of tumors from B to T lineage since some of T cell
lymphomas developed in C3H/Hej transgenic mice conserved the germline configu-
ration of Ig heavy chain genes.
Kaplan et al. (42-45) have shown the high incidence of T cell lymphomas of graft
origins in the irradiated mice that receive unirradiated thymus graft and have iso-
lated radiation leukemia virus (RadLV) as the agent that induces tumors of graft
origin by indirect mechanisms in irradiated recipients. The recent study by Lie-YUKAWA ET AL.
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berman et al. (46) has confirmed the indirect mechanism of radiation-induced lym-
phomagenesis buthasdemonstrated that such lymphomagenesisis mediated by the
transmissible agent that is not identical to RadLV. Recently it has also been reported
that irradiation ofhematopoieticstroma cellsinducesthe production of certain growth
factor(s) that support the development of myelogenous leukemia (47). Supposing
such an agent or a growth factor exists even at considerably low levels in normal
C3H/HeJ, it might positively affect the development or growth of T lymphoma in
theprelymphomatous transgenic mice of C3H/HeJ. Irradiation of B6 mice may in-
duce such an agent or growth factor and provide the environment to support the
T lymphoma development. However, the identification of viral agents or factors,
which influencethe development of T and B cell tumors, will require furtherstudies.
In contrast to Ep-myc transgenic mice produced by others (8, 18, 19, 48), our
C3H/HeJ transgenic mice developed mostly Tlymphomas, which represent various
differentiation stages ofT cells. Although a number oftransgenic mice carrying var-
ious activated oncogenes have been reported, the incidence of T lymphoma is con-
siderably low (see reference 49 for review). Recently it has been reported that mu-
rine leukemia virus (MuLV) infection accelerated the development of T lymphoma
in Ep.-pim-1 transgenic mice, although uninfected transgenic mice developed T lym-
phomas at a low frequency (5-10%) and after a relatively long latent period (3-7
mo) (50). Similarly to T lymphomas in our C3H/HeJ transgenic mice, tumors de-
veloped in E/A-pim-1 represented different T cell subpopulations, CD4+/CD8 +
tumors and CD4+/CD8 - tumors. Therefore, those transgenic mice and ours and
tumors developed in such mice will be very useful for the study of T cell differentia-
tion pathways, as well as for theelucidation ofthe mechanismofT lymphomagenesis.
Summary
The transgenic mice were produced by injecting eggs of B6 and C3H/HeJ mice
with the human Ep-myc gene. Preferential development of B lymphomas was ob-
served in the B6 transgenic mice, whereas the C3H/HeJ transgenic mice developed
mostly Tlymphomas. The phenotypic activation of B lineage cells but not of T lin-
eage cells wasdetected in the prelymphomatous transgenic mice of both strains. The
transgene was similarly expressed in B and T cells of the transgenic mice of both
strains. Theseresultssuggest that ahigh incidenceof Tlymphomasin theC3H/HeJ
transgenic mice may not be due to the preferential activation of or the preferential
Ep-myc expression in T lymphocytes. When the bone marrow or fetalliver cellsfrom
the prelymphomatous transgenic mice of both strains were transferred into irradi-
ated normal C3H/HeJ mice, most ofthe recipients developedTlymphomas. Moreover,
even when irradiated B6 mice received thehematopoietic stem cells from theprelym-
phomatous B6 transgenic mice, the incidenceofT lymphoma increased up to 50%.
These findings suggest that B6 and C3H/HeJ mice might provide the environment
that supports the development or growth of B and T lymphomas, respectively, and
that such an environment could be modified by irradiation of the mice.
We thank Dr. S. Tonegawa for providingthe EI,-myc gene, Dr. E. L. Barsumian for critical
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